UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...

The ResMed AirSense machines have a white-colored filter you replace every two weeks Replace the water tank that functions as the humidifier every six months. If your CPAP has an integrated or ...

ResMed has convinced investors that a reduction in obesity rates globally thanks to GLP-1 drugs such as Ozempic will not necessarily reduce demand for its ventilators and machines, which improve ...

Sleep apnea or other forms of the sleep disorder require an effective CPAP machine to enhance your health and sleep patterns. Surgeons use CPAP machines for sufferers of sleep apnea, which is a ...

Using a continuous positive airway pressure (CPAP) machine to treat sleep apnea comes with a potential risk of infection, including sinus infections and pneumonia. Luckily, this risk is extremely low.

ResMed on Tuesday announced that it has launched AirSense 11 in India. According to the company’s statement, it is the next-generation Continuous Positive Airway Pressure (CPAP) device designed ...

ResMed has beaten earnings forecasts in the second quarter due to higher sales of its sleep device products and masks despite fears that the take-up of weight-loss drugs would reduce demand as ...